Novo Nordisk after US delivery issues: New obesity drug launch set for H2 next year
It is not just in the US that significant demand for Novo Nordisk's obesity drug Wegovy is having an impact. The pharmaceutical firm now reports that new launches of the drug will not take place until during the second half of 2022.
.jpg)
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Major US demand for obesity drug obesity Wegovy – which has led to delivery problems for Novo Nordisk – mean that the Danish pharmaceutical company will not begin new launches of the medication before a year's time at the earliest, Novo tells MedWatch in an email.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
